Updates are available Correction dated 2024-06-17
Click to view Correction: https://doi.org/10.1038/s41375-024-02308-5
Updates are available Correction dated 2022-04-12
Click to view Correction: https://doi.org/10.1038/s41375-022-01567-4
-
Authors
Abdallah, Nadine https://orcid.org/0000-0001-9195-1589
Murray, David https://orcid.org/0000-0003-1720-335X
Dispenzieri, Angela https://orcid.org/0000-0001-8780-9512
Kapoor, Prashant https://orcid.org/0000-0002-4342-364X
Gertz, Morie A.
Lacy, Martha Q.
Hayman, Suzanne R.
Buadi, Francis K. https://orcid.org/0000-0003-3214-0203
Gonsalves, Wilson
Muchtar, Eli https://orcid.org/0000-0003-2210-2174
Leung, Nelson https://orcid.org/0000-0002-5651-1411
Dingli, David https://orcid.org/0000-0001-7477-3004
Kourelis, Taxiarchis https://orcid.org/0000-0001-8573-9434
Warsame, Rahma
Binder, Moritz https://orcid.org/0000-0001-9014-9658
Kyle, Robert A.
Rajkumar, S. Vincent
Kumar, Shaji https://orcid.org/0000-0001-5392-9284
- License Information
-
More Information
Article History
Received: 7 December 2021
Revised: 13 December 2021
Accepted: 21 December 2021
First Online: 29 January 2022
Change Date: 12 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-022-01567-4
Change Date: 17 June 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-024-02308-5
Competing interests
: PK is a principal investigator of research studies for which Mayo Clinic has received funding from AbbVie, Takeda, Sanofi, Janssen, Karyopharm, GlaxoSmithKline, Regeneron Pharmaceuticals, Ichnos Sciences and Amgen. He has served on the Medical advisory board meetings of Sanofi, Pharmacyclics, BeiGene, Cellectar, GSK, X4, and Karyopharm. AD received research funding from Celgene, Millennium Pharmaceuticals, Pfizer, and Janssen and received a travel grant from Pfizer. MAG served as a consultant for Millennium Pharmaceuticals and received honoraria from Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Novartis, GlaxoSmithKline, Prothena, Ionis Pharmaceuticals, and Amgen. MQL received research funding from Celgene. NL serves on an advisory board for Takeda Pharmaceuticals. SK served as a consultant for Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Janssen, and Bristol-Myers Squibb and received research funding from Celgene, Millennium Pharmaceuticals, Novartis, Onyx Pharmaceuticals, AbbVie, Janssen, and Bristol-Myers Squibb. DM has potential royalties on patents leased to the Binding Site. EM received honorarium from Janssen and consultation fee from Protego (fee paid to institution). The remaining authors declare no competing financial interests.
